



# DEPARTMENT OF DERMATOLOGY

---

1. Bullous Pemphigoid: A Case Series

Dr. Vidhi Malu

2. Non-invasive Dermatological Modalities for Clinical Examination

Dr. Shubhangi Gupta

3. Fractional Micro Needling Radiofrequency Treatment of Acne Scars

Dr. Nishtha Mishra

4. SIRT1, Vitiligo and Skin Cancer

Dr. Anushka Agarwal




# **Bullous Pemphigoid: A Case Series**

Dr Vidhi Malu

# Introduction

- BP is the **most common** autoimmune **subepidermal** blistering disease, typically affecting the **extremely aged**.
- However, there is lot of heterogeneity in its:-
  - clinical presentation,
  - variants,
  - location,
  - age of onset and
  - concurrent diseases

- Till 1953, all blistering diseases were grouped under Pemphigus (Gk: “**pemphix**”- blister) , when **Lever** first distinguished bullous pemphigoid from pemphigus—blisters being **subepidermal** in the **former** unlike **intraepidermal** in the **latter**.
- A decade later, **Jordon and Beutner** identified the hemidesmosomal antigens (**BPAg1 and BPAg2**).
- Hemidesmosomes are multi-protein complexes that connect the basal keratinocytes to the lamina densa.





# Case 1



**42 Y/ M**









2014



2019



2024


- Pruritic papular eruptions on limbs
- LP diagnosed clinically
- By a private practitioner
- Rx- oral and topical corticosteroids
- Partial relief of symptoms

- Oral ulcers

- Biopsies performed -leg plaque  
- trunk bulla
- Anti BPAg 180 antibodies: 59.97 RU/ml
- Serum IgE : 4361 IU/ml




# Biopsy - leg plaque - LP






Biopsy from bulla- BP



Direct immunofluorescence





- This case showing **concurrency** of LP and BP is an example of **overlap** between the two diseases called **Lichen planus pemphigoides**.
- Lesions of the two can be **independent** as in the index case or as **bullae over LP papule**.
- In LPP, autoantibodies target the **BPAg2** antigen, like in BP, but has a **younger age** of onset
- Pathogenesis: LP damaging basal layer → exposing antigens → causing epitope spreading → autoantibody formation → subepidermal bullae.

# Treatment


- Oral **betamethasone** pulse (twice weekly)
- Inj **omalizumab** (monoclonal anti-IgE)  
**300mg s/c** monthly.
- Cap **acitretin** (retinoid) **25mg OD**
- Topical clobetasol 0.05% cream.
- Marked clinical improvement



3 months



# Post treatment






# Case 2



**81 Y/M**













15 Y

Mar 2024

May 2024

Nov 2024

Dec 2024

HTN  
DM  
IHD

Torsemide  
Linagliptin


- Red, raised itchy papules

Non- bullous prodrome of BP

- Tense blisters
- Erosions
- Crusts
- Clinidipine

and insulin introduced

Significant improvement



# Post treatment







12:54





12:54

# Drug-induced bullous pemphigoid

- Loop diuretics (e.g, **torsemide** , furosemide)
- DPP-4 inhibitors (**linagliptin** , vildagliptin)
- Immune checkpoint inhibitors (nivolumab, pembrolizumab)
- TNF inhibitors
- ACE inhibitors
- Antibiotics (amoxicillin, ciprofloxacin) ,
- NSAIDs



# Proposed mechanisms of drug-induced BP

- DPP-4 inhibitors alter the immune response by decreasing CD26 expression on T-cells .
- HLA-DQB1\*03:01 allele in Japanese may increase risk for DPP-4i-induced BP.
- Loop diuretics- Alter hemidesmosomal proteins, exposing epitopes that trigger BP

# Case 3



**42 Y/F**









2017 June

Primary  
myeloproliferative  
neoplasm

(Essential  
thrombocythemia)

- Bone marrow aspirate-  
hypercellular marrow
- PLT - 814000
- Gene mutation study  
Jak2V67f +ve

2024 Dec

Biopsy- Bullous pemphigoid


**Rx**

Systemic corticosteroids

Topical high-potency corticosteroids


2025 Jan

Improvement





# Post treatment





## **BP with essential thrombocythemia (MPN) -a rare association**

- BP is commonly linked to hematological malignancies:
  - Acute myeloid leukaemia
  - Non- Hodgkin lymphoma
  - Mycosis fungoides
  - Chronic lymphocytic leukemia
  - Multiple myeloma
  - Hypereosinophilic syndrome

### **Pathophysiology :**

- Chronic inflammation and release of cytokines and interleukins may trigger BP.



# Case 4



**91/F**





2013


2015  
10th Sep

2015  
24th Sep

Diagnosed with Parkinsonism

Lesional skin Bx /DIF-  
features typical of BP

Appreciable  
improvement



Rx

Levodopa

Rx

Tetracycline, nicotinamide and dapsons







# Dyshidrosiform pemphigoid associated with neurological disorders

- Neurological disorders (**stroke, dementia, Parkinsonism, epilepsy, multiple sclerosis**) expose **BPAg1-n**, a spliced form of **BPAg1-e**, that stabilises the sensory neuron cytoskeleton.  
A large UK based study (**n=863**) of such cases lasting over a year found a 21% prevalence of BP. Autoantibodies generated may cross-react with BPAg1-e, leading to BP.
- The **first case** of dyshidrosiform pemphigoid caused by Parkinsonism in **India** was reported in 2016.

Case Report

## Dyshidrosiform pemphigoid with Parkinsonism in a nonagenarian Maharashtrian female

Behlim T, Sharma YK, Chaudhari ND, Dash K. Dyshidrosiform pemphigoid with Parkinsonism in a nonagenarian Maharashtrian female. Indian Dermatology Online Journal. 2014 Oct 1;5(4):482-4.



# Localised BP

- Sites involved: Pretibial, flexures, genitals, umbilicus, stomal, etc
- Seen in about 5-30% of the patients with BP.



Pretibial



Stomal



# Radiation aggravated pemphigoid





# Pemphigoid gestationis





# Childhood BP












# Non-invasive dermatological modalities for clinical examination

-Dr. Shubhangi Gupta



# Dermoscopy





# What is dermoscopy?

Technique to visualize structure that cannot be seen with the naked eye

Applications-

Trichoscopy

Mucoscopy

Nail fold capillaroscopy

Entomodermatoscopy

Inflammoscopy



# What is the need?

Bedside non-invasive

Enhanced diagnostic accuracy

Reduction in unnecessary biopsies

Monitoring skin lesions for prognosis and treatment progression

Useful for pediatric skin lesions



# Dermatoscopic tools





Handheld dermatoscope



Video dermatoscope







Integrated AI software

Higher magnification and resolution



Flexible handle- easy to examine scalp, nails, and mucosal regions



# Examples where dermoscopy helps in bedside diagnosis




# Infective versus non-infective lesions



# Angiokeratoma of Fordyce versus viral warts




A



1



B




2



## IMAGES IN CLINICAL MEDICINE

Stephanie V. Sherman, M.D., *Editor*

## Angiokeratoma of Fordyce



A 35-YEAR-OLD WOMAN PRESENTED TO THE DERMATOLOGY CLINIC WITH a 4-year history of itchy, wartlike lesions in her pubic region. The lesions bled when traumatized during shaving of the pubic hair. One year before presentation, cryotherapy had been administered for a presumed diagnosis of genital warts, but the lesions had not abated. Physical examination was notable for hyperpigmented, hyperkeratotic papules forming three plaques over the mons pubis (Panel A). Dermoscopy showed well-demarcated reddish-to-violaceous lacunae, representing dilated capillaries (Panel B, black arrows), and an overlying white veil of epidermal hyperkeratosis (Panel B, white arrows). A diagnosis of angiokeratoma of Fordyce was made. Angiokeratoma of Fordyce is a benign cutaneous vascular lesion characterized by capillary dilatation in the papillary dermis. The lesion is most typically seen on the genitals and is more common in men than in women. The prevalence increases with age. Angiokeratoma of Fordyce may be difficult to distinguish from other genital lesions, such as warts and verrucous hemangiomas. The patient underwent a single session of treatment with a neodymium:yttrium–aluminum–garnet (YAG) laser to reduce the vascularity of the lesions, followed by ablation with an erbium:YAG laser. During telephone follow-up 2 months after the procedure, the patient reported that the lesions had not recurred.

DOI: 10.1056/NEJMicm2407196

Copyright © 2024 Massachusetts Medical Society.



The NEW ENGLAND  
JOURNAL of MEDICINE

Namratha Puttur, M.B., B.S.  
Kshitiz Lakhey, M.B., B.S.


Dr. D.Y. Patil Medical College, Hospital,  
and Research Centre  
Pune, India  
drkshitizlakhey@gmail.com

This article was published on November 2,  
2024, at NEJM.org.




# Scarring versus non-scarring alopecia

Follicular openings on trichoscopy



Present



Non- cicatricial alopecia



Absent



Cicatricial alopecia



# Androgenetic alopecia vs lichen planopilaris






Androgenetic alopecia  
(non- scarring alopecia)



Lichen planopilaris  
(scarring alopecia)









# Non-scarring alopecia












# Trichotillomania






# Trichoscopy



# Trichoscale

•TrichoScale is an AI-enabled software tool used in trichoscopy for the quantitative analysis of hair and scalp conditions.





After regrowth



Summary

Hair Density

Measurement Area	0.922	cm <sup>2</sup>
Hair Count	0	N
Hair Density	0	N/cm <sup>2</sup>

Hair Cycle

Hair Rate Anagen	0	%
Hair Rate Telogen	100	%
Hair Count Anagen	0	N
Hair Count Telogen	0	N
Hair Density Anagen	0	N/cm <sup>2</sup>
Hair Density Telogen	0	N/cm <sup>2</sup>

Hair Growth

Initial Hair Length	0.50	mm
Regrowth Time	2.0	days
Average Growth Rate	0.00	mm/day

Thickness Groups

Hair Rate Terminal	0	%
Hair Rate Vellus	100	%
Hair Count Terminal	0	N
Hair Count Vellus	0	N
Hair Density Terminal	0	N/cm <sup>2</sup>
Hair Density Vellus	0	N/cm <sup>2</sup>
Mean Thickness	0	µm
Cumulative hair thickness	0.0	mm/cm <sup>2</sup>

Follicular Units

Total Follicular Units	0	N
Units (1 Hair)	0	N
Units (2 Hair)	0	N
Units (3)	0	N
Units (4+)	0	N
Units Density	0	N/cm <sup>2</sup>
Average Hair / Unit	0	N


General

Total Field Of View	1.393	cm <sup>2</sup>
Total Hairs	0	N

Pie Chart

Length

Thickness / Count





## General

Total Field Of View	1.393 cm <sup>2</sup>
Total Hairs	222 N

## Hair Density

Measurement Area	0.922 cm <sup>2</sup>
Hair Count	193 N
Hair Density	209 N/cm <sup>2</sup>

## Hair Cycle

Hair Rate Anagen	96 %
Hair Rate Telogen	4 %
Hair Count Anagen	159 N
Hair Count Telogen	7 N
Hair Density Anagen	201 N/cm <sup>2</sup>
Hair Density Telogen	8 N/cm <sup>2</sup>




## Thickness Groups

Hair Rate Terminal	52 %
Hair Rate Vellus	48 %
Hair Count Terminal	101 N
Hair Count Vellus	92 N
Hair Density Terminal	110 N/cm <sup>2</sup>
Hair Density Vellus	99 N/cm <sup>2</sup>
Mean Thickness	37 μm
Cumulative hair thickness	7.7 mm/cm <sup>2</sup>



# Follicular Units

Total Follicular Units	121 N
Units (1 Hair)	56 N
Units (2 Hair)	43 N
Units (3)	13 N
Units (4+)	9 N
Units Density	87 N/cm <sup>2</sup>
Average Hair / Unit	1.83 N







Pre-treatment



Post-treatment



# Hair Cycle

Hair Rate Anagen 96 %


Hair Rate Telogen 4 %

Hair Count Anagen 159 N


Hair Count Telogen 7 N

Hair Density Anagen 201 N/cm<sup>2</sup>

Hair Density Telogen 8 N/cm<sup>2</sup>



Anagen Telogen



Terminal Vellus

# Hair Cycle

Hair Rate Anagen 98 %


Hair Rate Telogen 2 %

Hair Count Anagen 201 N


Hair Count Telogen 5 N

Hair Density Anagen 254 N/cm<sup>2</sup>

Hair Density Telogen 5 N/cm<sup>2</sup>



Anagen Telogen



Terminal Vellus

After 3 sessions  
of HaiRestart



# Pigmentary dermatoses



**Melasma**



**Seborrheic keratoses**




**Acanthosis nigricans**





# Melasma






# Seborrheic keratoses





# Acanthosis nigricans





# Nail fold capillaroscopy



# Dermatomyositis






Heliotrope rash



Gottron's papules with overlying ulcers







# Systemic sclerosis




Mask like face



Salt and pepper pigmentation




Can be used as a **prognostic marker** as it helps in early detection of **Interstitial lung disease (ILD)**.





# Conclusion

Dermoscopy stands as a bridge between the visible and the microscopic, transforming mere observation into precision-driven diagnosis.



*Together, let us embrace this lens into the unseen, where science meets artistry in the pursuit of better healthcare.*





Thank  
you



# **Fractional microneedling radiofrequency treatment of acne scars**

Dr. Nishtha Mishra




# Acne scars: a lasting impact







Rolling Scars



Boxed Scars



Icepick Scars



*Rolling Scar*



*Boxcar Scar*



*Ice Pick Scar*



# Addressing acne scars: current approaches

Fractional Resurfacing and Acne Scars Revision

**Dermaroller**

**Surgical excision**

**Laser therapy**

HOW DOES IT WORK?

The background of the slide features a complex, abstract pattern of thin, overlapping red lines that create a sense of depth and movement, resembling a stylized architectural or organic structure. This pattern is set against a light, off-white background. A thin red horizontal line is positioned directly beneath the text 'HOW DOES IT WORK?'.A small, rectangular inset image at the bottom center of the slide shows a close-up of human skin. The skin is light-toned and exhibits several deep, vertical, and slightly irregular scars, characteristic of acne scars. The texture of the skin is visible, and the lighting is soft, highlighting the depth of the scars.



**Why do we need a newer  
modality?**




# Fractional microneedling radiofrequency

MNRF is a technique combining microneedling & RF energy, creating **controlled** micro-injuries while delivering RF energy and acts by:


- ↑ **Collagen & elastin** production
- ↑ Skin **remodeling** & improved texture
- ↓ Risk of **hyperpigmentation**














# Principle of MNRF





# Fitzpatrick skin types



1

*Very Fair*

*always burns  
cannot tan*



2

*Fair*

*usually burns  
sometimes tans*



3

*Medium*

*sometimes burns  
usually tans*



4

*Olive*

*rarely burns  
always tans*



5

*Brown*

*never burns  
always tans*



6

*Black*

*never burns  
always tans*

Post-inflammatory hyperpigmentation







# Study design & patient selection

- **Study type:** Retrospective
- **Sample size:** 55 patients (38 males, 17 females)
- **Study period:** January 2022 – December 2023
- **Approval:** Institutional ethics committee, Dr. D.Y. Patil Medical College
- **Inclusion criteria:**
  1. Diagnosed with acne scars
  2. Completed **4 MNRF sessions** (1-month intervals)
  3. Provided informed consent
- **Exclusion criteria:**
  1. Prior acne scar treatments













# Reduction in scar count





# Impact on mean DLQI scores


- Pre-treatment : 10.00
- Post-treatment : 3.147
- Difference is significant  
( $p < 0.0001$ )
- 95% Confidence  
Interval: -8.608 to -5.098  
(significant)





# Pain assessment during procedure

- It was done using the VAS (1-10)
- Mean VAS score:  $1.54 \pm 0.78$
- Indicates relatively **low pain** immediately post-procedure.
- Supports patient **compliance and treatment feasibility**.





# Results

- Significant reduction in acne scar **count** ( $p < 0.0001$ ).
- Improved DLQI scores indicating patient **well-being**.
- Minimal pain (VAS =  $1.54 \pm 0.78$ ) → **well-tolerated** treatment.



A vibrant watercolor splash in shades of purple, blue, orange, and pink surrounds a central white square. The splash has a soft, painterly texture with visible brushstrokes and some small dark specks scattered around it.

Thank  
you





# SIRT1, Vitiligo & Skin Cancer

Dr. Anushka Agarwal





# UV rays

01


- Skin loses the ability to absorb free radicals.
- These cause **damage** to **DNA**, proteins, and other cellular contents and lead to the development of skin cancers.

02


- **Early effects** – redness, **delayed tanning**, **skin thickening**, and **free radical formation**.
- **Long-term effects** – **faster aging**, weaker immunity, and **skin cancers**.

03

- **UV-A Radiation**: immediate darkening and early aging.
- **UV-B Radiation**: **1000 times** more likely to cause **sunburn**.
- **UV-C Radiation**: most dangerous, but filtered by the ozone layer








The Protective effect of

# Melanin

- Synthesized within **melanosomes** and transferred to keratinocytes
- Surrounds the **nucleus** forming a **supranuclear shield**
- Acts like a broadband **UV absorbant**
- Antioxidant
- **Free radical scavenger**
- SPF : 2 to 4





# Skin color X cancer

Risk of skin cancer

Highest


High

Lowest




Individuals with albinism

No melanin



Fair skinned individuals

Some melanin



Dark skinned individuals

Max melanin



# Vitiligo

## Patchy depigmenting disorder

- A **chronic** skin disorder affecting **1-2%** of Indians
- Leads to severe psychological stress and a loss of quality of life
- Treatment of choice: **UV-B**

## PARADOX

Surprisingly in Individuals with vitiligo

Decreased melanin



Lower risk of skin cancer

Compared to ethnicity matched individuals






## The Question



Why do people with vitiligo have a low risk of developing skin cancer

## Study design





# Detection of UV-B mediated DNA damage in cells




Detected with antibody against  $\gamma$ -H2AX

Detected with antibody against cyclobutane pyrimidine dimers

## Bioinformatic tools

Used to predict the potential **targets** of the most **differentially regulated miRNA**






# Results



## 17 differentially regulated miRNAs in vitiligo

5 upregulated, 12 downregulated



## miR 211-5p was the most downregulated

Suppresses keratinocyte proliferation and increases UV-mediated DNA damage




## Sirtuin 1 is a target of miR-211-5p

Promotes keratinocyte differentiation and protects cells from UV-mediated DNA damage



## MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) promotes SIRT1 expression

By inhibiting the expression of miR-211.  
SIRT1 is the final effector protein






# Novel pathway protects amelanotic cells of vitiligo

lncRNA MALAT1 suppresses miR 211 increasing the production of  
SIRT1 (the final effector protein)

## What is SIRT1




NAD-dependent  
deacetylase

Regulates cell **survival**

**Stress** response

Genomic **stability**




The longevity factor

Controls **metabolism**

Prevents **aging**

and **cancer**



Increased SIRT1 leads to

Decreased  **$\gamma$ -H2AX** positivity

Decreased **CPD** formation

Hallmarks of UV related **cell damage**



# Building on this breakthrough



## Next gen activators of SIRT1

- **Resveratrol** - 1g/day to activate SIRT.








- ## Oral sunscreens
- Application of sunscreens all over body - not practical
  - Oral activators of SIRT1 - Better Compliance
  - Used by wide range of individuals – SLE/ photoaging/ cancer



# White armor of vitiligo

- Our study established that vitiligo patients have a reduced incidence of skin cancer, suggesting a potential protective effect of vitiligo-associated immunity.
- A large population-based study in the USA of 25,000 vitiligo patients further confirmed lower cancer incidence rates.
- Extending this concept, a nationwide study in Korea of 1,07,400 vitiligo patients found reduced all-cause and cause-specific mortality in vitiligo patients across various systemic diseases.
- This indicates that immune mechanisms in vitiligo may offer broader systemic benefits.
- To prove this concept, we are conducting a unique sibling-based study, comparing vitiligo –affected with their unaffected siblings, to investigate the protective effects of vitiligo beyond skin cancer.





Genome-wide profiling reveals pervasive transcriptional alterations in fibroblasts derived from lesional skin in vitiligo including a reduced potential to proliferate. *Experimental Dermatology*. 2023 Apr

Gupta R, Misri R, Gupta A, Chowdhary M, Singh A.

Differential regulation of miR-21-5p delays wound healing of melanocyte-deprived vitiligo skin by modulating the expression of tumor-suppressors PDCD4 and Maspin. *Journal of Cellular Physiology*. 2022 Feb

Brahmbhatt HD, Gupta R, Gupta A, Rastogi S, Subramani D, Mobeen A, Batra VV, Singh A.

Whole exome-sequencing of vitiligo lesions indicate lower burden of somatic variations: implications in risk for non-melanoma skin cancers. *bioRxiv*. 2022 May

Gupta I, Shankrit S, Narta K, Ghazi M, Grover R, Pandey R, Kar HK, Menon SM, Gupta A, Yenamandra VK, Singh A

The long noncoding RNA MALAT1 suppresses miR-211 to confer protection from ultraviolet-mediated DNA damage in vitiligo epidermis by upregulating sirtuin 1. *British Journal of Dermatology*. 2021 Jun

Brahmbhatt HD, Gupta R, Gupta A, Rastogi S, Misri R, Mobeen A, Ghosh A, Kothari P, Sitaniya S, Scaria V, Singh A.

Whole exome sequencing helps in accurate molecular diagnosis in siblings with a rare co-occurrence of paternally inherited 22q12 duplication and autosomal recessive non-syndromic ichthyosis. 2015 Jul

Gupta A, Sharma Y, Deo K, Vellarikkal S, Jayarajan R, Dixit V, Verma A, Scaria V, Sivasubbu S.

Quality of life in vitiligo: Relationship to clinical severity and demographic data. *Pigment International*. 2017 Jul  
Patvekar MA, Deo KS, Verma S, Kothari P, Gupta A.

Lesional skin in vitiligo exhibits delayed in vivo reepithelialization compared to the nonlesional skin. *Wound Repair and Regeneration*. 2020 Mar

Gupta A, Chauhan A, Priya A, Mantri B, Wadhokar M, Dalave K, Shah B, Gokhale RS, Batra VV, Singh A

Mapping architectural and transcriptional alterations in non-lesional and lesional epidermis in vitiligo. *Scientific Reports*. 2017 Aug

Singh A, Gotharwal V, Junni P, Vijayan V, Tiwari M, Ganju P, Kumar A, Sharma P, Fatima T, Gupta A, Holla A.



I am not this hair,  
I am not this skin,  
I am the soul  
that  
lives within.

- Rumi

---

Thank You

